Table 3. Population characteristics for patients with renal impairment treated with novel agents.

		HDT with renal impairment			Non-HDT with renal impairment
		Novel treatment			Novel treatment
		Yes	No	P	Yes	No	P
No. of patients		57	166		135	308
Mean age		59	58	0.62	75	75	0.67
Type of MM, %
	IgG	49.1	50		53.3	55.8
	IgA	31.6	22.9		17.8	19.8
	BJ	15.8	20.5		25.2	20.5
	Other	3.5	5.4		2.2	2.3
	Missing	0	1.2		1.5	1.6
Laboratory values, mean
	Albumin, g/L	30	33	0.03	33	32	0.76
	Hb, g/L	98	100	0.46	102	101	0.70
	Ca, mmol/L	2.5	2.6	0.34	2.6	2.6	0.24
	B2M, mg/L	10.2	9.2	0.72	8.3	8.0	0.78
	Creatinine	314	238	0.04	295	217	0.002
Stage of renal function, %
	3	52.6	59.6		60	67.2
	4	21.1	23.5		18.5	19.2
	5	26.3	16.9		21.5	13.6

The HDT patients are those that at some point have received high-dose treatment, irrespective of treatment line and the non-HDT those that have not. Patients classified has having received novel drugs implies that they have received this treatment in one or more treatment lines.

HDT, high-dose treated; non-HDT, non-high-dose treated; MM, multiple myeloma; IgG, immunoglobulin G; IgA, immunoglobulin A; BJ, Bence Jones; Hb, hemoglobin; Ca, calcium; β2μ, beta-2-mikroglobulin.